ArticleScientific reports2025
m7G-related gene signatures determine prognosis in triple-negative breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC), which lacks targeted treatment options, continues to pose a major clinical hurdle. This study investigated the molecular complexities of TNBC, with a focus on m7G modifications, the immune microenvironment, and their influence on patient prognosis. An integrated analysis of m7G-related genes facilitated the creation of a risk model based on differentially expressed m7G-related genes, which effectively stratified patients with TNBC into low- and high-risk groups, with the low-risk group demonstrating a marked survival advantage. Immune cell infiltration analysis revealed substantial differences between risk groups, suggesting a potential association between m7G-related risk and immune landscape modulation. Genomic profiling identified distinct mutational patterns, with TP53 mutations predominant in the high-risk group and PIK3CA mutations in the low-risk group. Chemosensitivity analysis indicated the potential for tailored drug responses, highlighting the utility of the m7G-related risk score in guiding personalized therapeutic approaches. Additionally, a nomogram incorporating the risk score, stage, and M stage was developed, providing a valuable tool for predicting 3-, 5-, and 10-year survival probabilities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.